RT Journal Article
SR Electronic
T1 Delayed rise of oral fluid antibodies, elevated BMI, and absence of early fever correlate with longer time to SARS-CoV-2 RNA clearance in an longitudinally sampled cohort of COVID-19 outpatients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.02.21252420
DO 10.1101/2021.03.02.21252420
A1 Annukka A. R. Antar
A1 Tong Yu
A1 Nora Pisanic
A1 Razvan Azamfirei
A1 Jeffrey A. Tornheim
A1 Diane M. Brown
A1 Kate Kruczynski
A1 Justin P. Hardick
A1 Thelio Sewell
A1 Minyoung Jang
A1 Taylor Church
A1 Samantha N. Walch
A1 Carolyn Reuland
A1 Vismaya S. Bachu
A1 Kirsten Littlefield
A1 Han-Sol Park
A1 Rebecca L. Ursin
A1 Abhinaya Ganesan
A1 Oyinkansola Kusemiju
A1 Brittany Barnaba
A1 Curtisha Charles
A1 Michelle Prizzi
A1 Jaylynn R. Johnstone
A1 Christine Payton
A1 Weiwei Dai
A1 Joelle Fuchs
A1 Guido Massaccesi
A1 Derek T. Armstrong
A1 Jennifer L. Townsend
A1 Sara C. Keller
A1 Zoe O Demko
A1 Chen Hu
A1 Mei-Cheng Wang
A1 Lauren M. Sauer
A1 Heba H. Mostafa
A1 Jeanne C. Keruly
A1 Shruti H. Mehta
A1 Sabra L. Klein
A1 Andrea L. Cox
A1 Andrew Pekosz
A1 Christopher D. Heaney
A1 David L. Thomas
A1 Paul W. Blair
A1 Yukari C. Manabe
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.03.02.21252420.abstract
AB Background Sustained molecular detection of SARS-CoV-2 RNA in the upper respiratory tract (URT) in mild to moderate COVID-19 is common. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection.Methods Ninety-five outpatients self-collected mid-turbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. Samples were tested for viral RNA, virus culture, and SARS-CoV-2 and other human coronavirus antibodies, and associations were estimated using Cox proportional hazards models.Results Viral RNA clearance, as measured by SARS-CoV-2 RT-PCR, in 507 URT samples occurred a median (IQR) 33.5 (17-63.5) days post-symptom onset. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR positive samples tested. All participants but one with positive virus culture were negative for concomitant oral fluid anti-SARS-CoV-2 antibodies. The mean time to first antibody detection in oral fluid was 8-13 days post-symptom onset. A longer time to first detection of oral fluid anti-SARS-CoV-2 S antibodies (aHR 0.96, 95% CI 0.92-0.99, p=0.020) and BMI ≥ 25kg/m2 (aHR 0.37, 95% CI 0.18-0.78, p=0.009) were independently associated with a longer time to SARS-CoV-2 viral RNA clearance. Fever as one of first three COVID-19 symptoms correlated with shorter time to viral RNA clearance (aHR 2.06, 95% CI 1.02-4.18, p=0.044).Conclusions We demonstrate that delayed rise of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever are independently associated with delayed URT viral RNA clearance.Competing Interest StatementDr. Mehta received speaker fees from Gilead Sciences. No other conflicts.Clinical TrialNCT04496466Funding StatementThis work was supported by the Johns Hopkins University School of Medicine COVID-19 Research and Response Program Fund and the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program. This research has been facilitated by the infrastructure and resources provided by the Johns Hopkins University Center for AIDS Research. The project described was supported by Grant Number 1P30AI094189 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institute of Health. We thank the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells and acknowledge the Centers for Disease Control and Prevention, BEI Resources, NIAID, NIH for SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-5228. Salary support for AARA from NIH/NIAID (K08AI143391), YCM from NIH (U54EB007958-12, U5411090366, U54HL143541-02S2, UM1AI068613), JAT from NIH/NIAID (K23AI135102). AP was supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N272201400007C. ALC & SLK were supported by NIH U54CA260492. Funding was also provided by the FIA Foundation, a gift from the GRACE Communications Foundation (CDH, NP, KK), NIAID grant R21AI139784 (CDH and NP), National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973 (CDH, NP, KK), NIAID grant R01AI130066 and NIH grant U24OD023382 (CDH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is not currently available, but can be made available upon request.